MedTrace Logo

Study of NTBC for Tyrosinemia I

NCT00004443 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-03-25

No results posted yet for this study

Summary

OBJECTIVES: I. Assess the safety and efficacy of NTBC in children with tyrosinemia I.

II. Evaluate the effects of NTBC on survival, rate of neurologic crises, improvement in renal tubular damage, reduction in the need for liver transplantation, and reduction in the development of hepatocarcinoma in these patients.

Conditions

  • Tyrosinemia I

Interventions

DRUG

NTBC

Sponsors & Collaborators

Principal Investigators

  • C. Ronald Scott · University of Washington

Study Design

Purpose
TREATMENT

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-10-31
Completion
2006-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004443 on ClinicalTrials.gov